{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:41:19Z","timestamp":1782834079762,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Although Fanconi syndrome (FS) induced by valproate (VPA) has occasionally been reported, the detailed clinical features of the disease remain unclear. The aim of this study was to elucidate the clinical features of patients with VPA-induced FS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched Chinese and English databases for all original studies, clinical reports, and case reports on VPA-induced FS published before March 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 29 articles including 54 patients (28 males and 24 females) were included. The patients had a median age of 7 years (range 2\u201334 years), had severely disabled (87.0%), tube feeding (64.8%), and received an average of 1.8 medications other than VPA. The median duration of VPA treatment was 4 years (range 0.7\u201315.5). Pathological fractures (25.9%), unexplained fever (11.1%), muscle weakness (9.3%), and edema (9.3%) were the most common symptoms, while 18 patients were diagnosed in incidental laboratory tests. Blood tests revealed hypokalemia (69.2%), hypophosphatemia (98.0%), and hypouricemia (93.3%). Urinalysis revealed glucosuria (96.1%), proteinuria (100.0%), generalized hyperaminoaciduria (100.0 %), \u03b22 macroglobulin (100.0%). Decreased percent total reabsorption of phosphate (%TRP) found in 94.1% of patients, and increased fractional excretion of uric acid (FEUA) were found in 100% of patients. The median time to resolution of FS after discontinuation of drug therapy was 3 months (range 0.25\u201318).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The possibility of FS needs to be considered with long-term VPA administration, especially in young, tube-fed, severely disabled patients who are co-administered with anticonvulsants. Patients receiving VPA should have regular blood and urine tests. Abnormal laboratory values returned to normal levels after VPA discontinuation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.945244","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T04:50:41Z","timestamp":1663303841000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Valproic-induced Fanconi syndrome: Clinical features, risk factors, diagnosis and management"],"prefix":"10.3389","volume":"9","author":[{"given":"Chunjiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.pcl.2018.09.002","article-title":"Fanconi syndrome","volume":"66","author":"Foreman","year":"2019","journal-title":"Pediatr Clin North Am."},{"key":"B2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1053\/ajkd.2003.50037","article-title":"Drug-induced Fanconi's syndrome","volume":"41","author":"Izzedine","year":"2003","journal-title":"Am J Kidney Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMcp2024526","article-title":"Initial management of seizure in adults","volume":"385","author":"Smith","year":"2021","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1136\/bmj.e281","article-title":"Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance","volume":"344","author":"Nunes","year":"2012","journal-title":"BMJ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/0002-9343(88)90055-1","article-title":"Side effects of valproate","volume":"84","author":"Dreifuss","year":"1988","journal-title":"Am J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0387-7604(93)90055-D","article-title":"Urinary excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase by patients with epilepsy","volume":"15","author":"Novo Mde","year":"1993","journal-title":"Brain Dev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/BF01972897","article-title":"Renal tubular dysfunction following treatment with anti-epileptic drugs","volume":"153","author":"Korinthenberg","year":"1994","journal-title":"Eur J Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s004670000535","article-title":"Renal tubular dysfunction in epileptic children on valproic acid therapy","volume":"16","author":"Altunba\u015fak","year":"2001","journal-title":"Pediatr Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00467-013-2512-x","article-title":"The effects of sodium valproate on the renal function of children with epilepsy","volume":"29","author":"Knights","year":"2014","journal-title":"Pediatr Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0022-3476(81)80736-6","article-title":"Valproic acid: a possible cause of proximal tubular renal syndrome","volume":"98","author":"Lenoir","year":"1981","journal-title":"J Pediatr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1528-1157.1999.tb00781.x","article-title":"Topiramate and metabolic acidosis","volume":"40","author":"Wilner","year":"1999","journal-title":"Epilepsia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s00467-005-1827-7","article-title":"Secondary renal Fanconi syndrome caused by valproate therapy","volume":"20","author":"Watanabe","year":"2005","journal-title":"Pediatr Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/ejpn.2000.0378","article-title":"Increased urinary excretion of tubular enzymes and proteins in children with epilepsy","volume":"4","author":"Korinthenberg","year":"2000","journal-title":"Eur J Paediatr Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"105370","DOI":"10.1016\/j.nbd.2021.105370","article-title":"Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder","volume":"155","author":"Van Bergen","year":"2021","journal-title":"Neurobiol Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pediatrneurol.2022.03.001","article-title":"Fanconi syndrome secondary to sodium valproate therapy: experience and literature review","volume":"130","author":"Sturla \u00c1lvarez","year":"2022","journal-title":"Pediatr Neurol."},{"key":"B16","first-page":"15","article-title":"Hypochloremia as a consequence of anion gap metabolic acidosis","volume":"104","author":"Madias","year":"1984","journal-title":"J Lab Clin Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"bcr03.2009.1697","DOI":"10.1136\/bcr.03.2009.1697","article-title":"An unusual case of extreme hypernatraemia","volume":"2009","author":"Anand","year":"2009","journal-title":"BMJ Case Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"bcr1220115359","DOI":"10.1136\/bcr.12.2011.5359","article-title":"Anticonvulsant-induced rickets and nephrocalcinosis","volume":"2012","author":"Lau","year":"2012","journal-title":"BMJ Case Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1258\/000456304322880104","article-title":"Topiramate increases biochemical risk of nephrolithiasis","volume":"41","author":"Lamb","year":"2004","journal-title":"Ann Clin Biochem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000188869","article-title":"Immunologically mediated chronic tubulo-interstitial nephritis caused by valproate therapy","volume":"72","author":"Fukuda","year":"1996","journal-title":"Nephron."},{"key":"B21","first-page":"1101","article-title":"Case report of chronic tubulo-interstitial nephritis","volume":"34","author":"Watanabe","year":"1992","journal-title":"Nihon Jinzo Gakkai Shi."},{"key":"B22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1046\/j.1523-1755.2001.060002804.x","article-title":"Drug-induced acute interstitial nephritis","volume":"60","author":"Rossert","year":"2001","journal-title":"Kidney Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.pediatrneurol.2014.09.007","article-title":"Fever of unknown origin as the initial manifestation of valproate-induced Fanconi syndrome","volume":"51","author":"Nozaki","year":"2014","journal-title":"Pediatr Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.11251\/ojjscn.43.233","article-title":"Three cases of Fanconi syndrome associated with valproate sodium treatment","volume":"43","author":"Inoue","year":"2011","journal-title":"No To Hattatsu."},{"key":"B25","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S0140-6736(85)91481-3","article-title":"Valproic acid associated abnormalities of carnitine metabolism","volume":"1","author":"Murphy","year":"1985","journal-title":"Lancet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/nep.13012","article-title":"Mechanism of valproic acid-induced Fanconi syndrome involves mitochondrial dysfunction and oxidative stress in rat kidney","volume":"23","author":"Heidari","year":"2018","journal-title":"Nephrology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10157-018-1581-3","article-title":"Sodium valproate-induced Fanconi syndrome in two severely disabled patients receiving carnitine supplementation","volume":"23","author":"Ono","year":"2019","journal-title":"Clin Exp Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1469-8749.2009.03402.x","article-title":"Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children","volume":"52","author":"Rauchenzauner","year":"2010","journal-title":"Dev Med Child Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3109\/15513819309048273","article-title":"Renal toxicity induced by valproic acid (Depakene)","volume":"13","author":"Hawkins","year":"1993","journal-title":"Pediatr Pathol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1056\/NEJMoa0905647","article-title":"A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome","volume":"362","author":"Magen","year":"2010","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000313962","article-title":"Toward understanding renal Fanconi syndrome: step by step advances through experimental models","volume":"169","author":"Sirac","year":"2011","journal-title":"Contrib Nephrol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.945244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T04:50:48Z","timestamp":1663303848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.945244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":31,"alternative-id":["10.3389\/fmed.2022.945244"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.945244","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"article-number":"945244"}}